ArticleMolecular cancer therapeutics2014

XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Yan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.